Loading…
Reported covered position: Former Member of Congress
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: FORD MOTOR COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to electric vehicles; manufacturing tax incentives; 48C, 45X, 30C, and 30D tax credits; tax credits for battery manufacturing investment and production; related provisions in H.R. 1, One Big Beautiful Bill Act".
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SANOFI, U.S. · Firm: WILLIAMS AND JENSEN, PLLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.
Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.
Source: Senate LDA
| SANOFI, U.S. |
| 8 |
| 2024–2025 |
| ZOETIS | 8 | 2024–2025 |
| COLONIAL PIPELINE | 7 | 2024–2025 |
| PFIZER | 7 | 2024–2025 |
| ELI LILLY & COMPANY | 6 | 2024–2025 |
| FORD MOTOR COMPANY | 6 | 2024–2025 |
| CENTENE CORPORATION | 5 | 2025 |
| PLASMA PROTEIN THERAPEUTICS ASSOCIATION | 5 | 2024–2025 |
| WORLD DOG ALLIANCE (HONG KONG) LIMITED | 4 | 2025 |
| BRISTOL-MYERS SQUIBB COMPANY | 3 | 2025 |
| ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) | 3 | 2024 |
| PAULSON & CO. INC. | 3 | 2025 |
| ACCESS TO HEALTH FOUNDATION | 2 | 2025 |
| EPC POWER | 2 | 2025 |
| RESEARCH SOCIETY ON ALCOHOL (FORMERLY KNOWNS AS RESEARCH SOCIETY ON ALCOHOLISM) | 2 | 2024 |
| TE CONNECTIVITY, INC. | 2 | 2025 |
| THE JED FOUNDATION | 2 | 2024 |
| WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) | 2 | 2024 |
| DR. EMIL KAKKIS | 1 | 2023 |
| NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES | 1 | 2024 |
| NOVOCURE INC. | 1 | 2025 |
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SANOFI, U.S. · Firm: WILLIAMS AND JENSEN, PLLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Medication affordability and access; general diabetes prevention. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. 340B.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER · Firm: WILLIAMS AND JENSEN, PLLC
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER · Firm: WILLIAMS AND JENSEN, PLLC
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER · Firm: WILLIAMS AND JENSEN, PLLC
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. HR. 1, One Big Beautiful Bill Act, MFN drug pricing proposals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: WILLIAMS AND JENSEN, PLLC
Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: WILLIAMS AND JENSEN, PLLC
Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: FORD MOTOR COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to electric vehicles; manufacturing tax incentives; 48C, 45X, 30C, and 30D tax credits; tax credits for battery manufacturing investment and production; related provisions in H.R. 1, One Big Beautiful Bill Act".
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: WILLIAMS AND JENSEN, PLLC
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: SANOFI, U.S. · Firm: WILLIAMS AND JENSEN, PLLC
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER · Firm: WILLIAMS AND JENSEN, PLLC
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.
DMEPOS Relief Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
DMEPOS Relief Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
DMEPOS Relief Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
SOAR Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
SOAR Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
SOAR Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
Pipeline Safety. Promoting Innovation in Pipeline Efficiency and Safety (PIPES) Act of 2025 (H.R. 5301). Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Proposals to address idled pipelines, including the pending Notice of Proposed Rulemaking on Pipeline Operational Status.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: NOVOCURE INC. · Firm: WILLIAMS AND JENSEN, PLLC
Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: NOVOCURE INC. · Firm: WILLIAMS AND JENSEN, PLLC
Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
SOAR Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
SOAR Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
SOAR Act of 2025
Client: ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: NOVOCURE INC. · Firm: WILLIAMS AND JENSEN, PLLC
Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: NOVOCURE INC. · Firm: WILLIAMS AND JENSEN, PLLC
Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies. H.R. 3417.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies. H.R. 3417.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage issues. Policies impacting U.S. address to the Covid-19 pandemic. Telehealth policies. H.R. 3417.
FAIR Act
Client: ELEVANCE HEALTH, INC. (FORMERLY REPORTED AS ANTHEM, INC.) · Firm: WILLIAMS AND JENSEN, PLLC
Legislative and regulatory issues regarding Medicaid managed care; Medicare Advantage program. Telehealth policies. H.R. 3417.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
Preparing for All Hazards and Pathogens Reauthorization Act
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421). American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
EMPOWER Act
Client: NATIONAL ASSOCIATION OF REHABILITATION PROVIDERS AND AGENCIES · Firm: WILLIAMS AND JENSEN, PLLC
Medicare coverage and reimbursement for therapy services and rehabilitation telehealth services; Medicare payment reform for post-acute care services; Matters affecting bundled payments and value-based reimbursement; Proposals to extend coverage and payment for telehealth services; S2459, the Empower Act HR 4878.
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
Enhancing Mental Health and Suicide Prevention Through Campus Planning Act
Client: THE JED FOUNDATION · Firm: WILLIAMS AND JENSEN, PLLC
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act.
Enhancing Mental Health and Suicide Prevention Through Campus Planning Act
Client: THE JED FOUNDATION · Firm: WILLIAMS AND JENSEN, PLLC
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act. S.1409--Kids Online Safety Act.
Enhancing Mental Health and Suicide Prevention Through Campus Planning Act
Client: THE JED FOUNDATION · Firm: WILLIAMS AND JENSEN, PLLC
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act.
Enhancing Mental Health and Suicide Prevention Through Campus Planning Act
Client: THE JED FOUNDATION · Firm: WILLIAMS AND JENSEN, PLLC
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act. S.1409--Kids Online Safety Act.
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). 2023 Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Researcha nd Development Act" (HR 7073).
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Researcha nd Development Act" (HR 7073).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Next Generation Pipelines Research and Development Act
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
Next Generation Pipelines Research and Development Act
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). 2023 Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Researcha nd Development Act" (HR 7073).
Next Generation Pipelines Research and Development Act
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
Next Generation Pipelines Research and Development Act
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Researcha nd Development Act" (HR 7073).
Pipeline Safety, Modernization, and Expansion Act of 2024
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Researcha nd Development Act" (HR 7073).
Pipeline Safety, Modernization, and Expansion Act of 2024
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
Pipeline Safety, Modernization, and Expansion Act of 2024
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). 2023 Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Researcha nd Development Act" (HR 7073).
Pipeline Safety, Modernization, and Expansion Act of 2024
Client: COLONIAL PIPELINE · Firm: WILLIAMS AND JENSEN, PLLC
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
End Chinese Dominance of Electric Vehicles in America Act of 2024
Client: FORD MOTOR COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to electric vehicles. H.R.7980 - End Chinese Dominance of Electric Vehicles in America Act of 2024.
End Chinese Dominance of Electric Vehicles in America Act of 2024
Client: FORD MOTOR COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to electric vehicles. H.R.7980 - End Chinese Dominance of Electric Vehicles in America Act of 2024.
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
Competitive Bidding Relief Act of 2023
Client: OWENS & MINOR, INC. · Firm: WILLIAMS AND JENSEN, PLLC
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act. S.1409--Kids Online Safety Act.
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act. S.1409--Kids Online Safety Act.
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY & COMPANY · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK INC. · Firm: WILLIAMS AND JENSEN, PLLC
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Issues related to pharmaceutical tariffs and related trade agreements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACCESS TO HEALTH FOUNDATION via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOETIS via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Animal health, issues impacting medicines and vaccines for animals.
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TE CONNECTIVITY, INC. via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Actions under Section 301 of the Trade Act of 1974, IEEPA, Section 232 of the Trade Expansion Act of 1962, and other trade-related authorities; export control actions and investment control proposals; other trade actions and developments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs.
Support for obesity drug coverage and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Medicare coverage issue for non-opioid product. Reauthorization of NOPAIN Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.
ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
FY26 Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Outreach on renewable energy project in Taoyuan City, Taiwan; U.S. International Development Finance Corporation which is not an option in the drop down box.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
FORD MOTOR COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Monitor issues related to implementation of and guidance on energy and manufacturing provisions enacted in PL 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EPC POWER via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Educate policymakers regarding EPC's products and capabilities, as well as proposals to ensure a secure supply chain for inverters.
Educate policymakers regarding EPC's products and capabilities, as well as proposals to ensure a secure supply chain for inverters.
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Strategic National Stockpile procurement issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain.
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.
Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.
CENTENE CORPORATION via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · Q4
Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.
Issues related to Advance Premium Tax Credits (APTCs) and cost-sharing reductions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
WORLD DOG ALLIANCE (HONG KONG) LIMITED via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · 4T
Issues related to the consumption of dog and cat meat.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
SOLVD HEALTH via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · 4T
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NOVOCURE INC. via WILLIAMS AND JENSEN, PLLC
2025 · fourth_quarter · RR
Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
PAULSON & CO. INC. via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · 3T
Monitoring state of play on housing.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ZOETIS via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Animal health, issues impacting medicines and vaccines for animals.
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs.
Support for obesity drug coverage and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Medicare coverage issue for non-opioid product. Reauthorization of NOPAIN Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.
Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.
ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
FY26 Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
EPC POWER via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Educate policymakers regarding EPC's products and capabilities, as well as proposals to ensure a secure supply chain for inverters. Proposed changes to IRC 45X.
Educate policymakers regarding EPC's products and capabilities, as well as proposals to ensure a secure supply chain for inverters. Proposed changes to IRC 45X.
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Strategic National Stockpile procurement issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain.
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.
Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Outreach on renewable energy project in Taoyuan City, Taiwan; U.S. International Development Finance Corporation which is not an option in the drop down box.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
TE CONNECTIVITY, INC. via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Actions under Section 301 of the Trade Act of 1974, IEEPA, Section 232 of the Trade Expansion Act of 1962, and other trade-related authorities; export control actions and investment control proposals; other trade actions and developments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
FORD MOTOR COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to electric vehicles; manufacturing tax incentives; 48C, 45X, 30C, and 30D tax credits; tax credits for battery manufacturing investment and production; related provisions in H.R. 1, One Big Beautiful Bill Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to pharmaceutical tariffs and related trade agreements.
Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.
Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.
ACCESS TO HEALTH FOUNDATION via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to individual insurance coverage, ACA premium subsidies, rural healthcare access, and health and wellness in the MAHA movement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.
Issues related to Advance Premium Tax Credits (APTCs) and cost-sharing reductions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
COLONIAL PIPELINE via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Provide information regarding Colonial Pipeline and its operations, its role in delivering refined products, and potential new projects. General issues affecting interstate refined product pipelines. Pipeline and energy infrastructure cybersecurity, including TSA security directives, and Enhancing Surface Cyber Risk Management Notice of Proposed Rulemaking (89 FR 88488-88592).
Pipeline Safety. Promoting Innovation in Pipeline Efficiency and Safety (PIPES) Act of 2025 (H.R. 5301). Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Proposals to address idled pipelines, including the pending Notice of Proposed Rulemaking on Pipeline Operational Status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WORLD DOG ALLIANCE (HONG KONG) LIMITED via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Issues related to the consumption of dog and cat meat.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
SOLVD HEALTH via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · Q3
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · third_quarter · RA
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval.
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval.
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval.
ZOETIS via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Animal health , issues impacting medicines and vaccines for animals.
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Medication affordability and access; general diabetes prevention. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. 340B.
Support for obesity drug coverage and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
RAYNER via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Medicare coverage issue for non-opioid product. Reauthorization of NOPAIN Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
PAULSON & CO. INC. via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Monitoring state of play on housing.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Issues related to competitive bidding for home medical equipment; patient access to respiratory therapy including non-invasive ventilation and related reimbursement; DMEPOS Relief Act of 2025 [H.R. 2005]; the Supplemental Oxygen Access Reform [SOAR] Act of 2025 [H.R. 2902, S. 1406]); and promoting electronic prescribing platforms.
FY26 Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Outreach on renewable energy project in Taoyuan City, Taiwan.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS)
FORD MOTOR COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Issues related to electric vehicles; manufacturing tax incentives; 48C, 45X, 30C, and 30D tax credits; tax credits for battery manufacturing investment and production; related provisions in H.R. 1, One Big Beautiful Bill Act".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Policies impacting Medicare Part D and Part B reimbursement policies. "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. HR. 1, One Big Beautiful Bill Act, MFN drug pricing proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences. Strategic National Stockpile procurement issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.
Issues related to Advance Premium Tax Credits (APTCs) and cost-sharing reductions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLONIAL PIPELINE via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Provide information regarding Colonial Pipeline and its operations, its role in delivering refined products, and potential new projects. General issues affecting interstate refined product pipelines. Pipeline and energy infrastructure cybersecurity, including TSA security directives, and Enhancing Surface Cyber Risk Management Notice of Proposed Rulemaking (89 FR 88488-88592).
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Proposals to address idled pipelines, including the pending Notice of Proposed Rulemaking on Pipeline Operational Status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WORLD DOG ALLIANCE (HONG KONG) LIMITED via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Issues related to the consumption of dog and cat meat.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
SOLVD HEALTH via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · Q2
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WORLD DOG ALLIANCE (HONG KONG) LIMITED via WILLIAMS AND JENSEN, PLLC
2025 · second_quarter · RR
Encourage the Administration and Congress to promote a global ban on the consumption of dog and cat meat and to support an international treaty addressing this issue.
FORD MOTOR COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Issues related to electric vehicles; manufacturing tax incentives; 48C, 45X, 30C, and 30D tax credits; tax credits for battery manufacturing investment and production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOETIS via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Animal health , issues impacting medicines and vaccines for animals.
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Support for obesity drug coverage and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158).
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158).
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Pharmacy benefit manager reform proposals.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals.
PAULSON & CO. INC. via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Monitoring state of play on housing.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ACCENDRA HEALTH, INC. (FORMERLY "OWENS & MINOR, INC.") via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Issues related to durable medical equipment reimbursement. Issues related to patient access to respiratory therapy including non-invasive ventilation and related reimbursement.
FY26 Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Outreach on renewable energy project in Taoyuan City, Taiwan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Issues related to Medicaid, Medicare Advantage, behavioral health and prior authorization.
Issues related to upcoming expiration of the Advance Premium Tax Credits (APTCs).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
COLONIAL PIPELINE via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Provide information regarding Colonial Pipeline and its operations, its role in delivering refined products, and potential new projects. General issues affecting interstate refined product pipelines. Pipeline and energy infrastructure cybersecurity, including TSA security directives, and Enhancing Surface Cyber Risk Management Notice of Proposed Rulemaking (89 FR 88488-88592).
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Proposals to address idled pipelines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLVD HEALTH via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · Q1
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health organizations on the value of AvertD and other SOLVD products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via WILLIAMS AND JENSEN, PLLC
2025 · first_quarter · RR
Issues related to Medicaid; Issues related to Medicare Advantage; Issues related to behavioral health; Issues related to prior authorization. Issues related to upcoming expiration of the Advance Premium Tax Credits (APTCs).
Issues related to Medicaid; Issues related to Medicare Advantage; Issues related to behavioral health; Issues related to prior authorization. Issues related to upcoming expiration of the Advance Premium Tax Credits (APTCs).
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · 4A
Outreach on renewable energy project in Taoyuan City, Taiwan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WISCONSIN PHYSICIANS SERVICE INSURANCE CORPORATION (DBA WPS HEALTH SOLUTIONS) via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · 4T
Issues related to mental health; insurance issues related to Medicare coverage, Medicare Advantage issues; issues related to CMS; issues related to military health TRICARE program, Veterans Health Issues, NDAA; telehealth issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESEARCH SOCIETY ON ALCOHOL (FORMERLY KNOWNS AS RESEARCH SOCIETY ON ALCOHOLISM) via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · 4T
General education to advance federal funding and policies to support continued alcohol research and strategies to address alcohol-related disorders.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Matters affecting plasma donation and potential plasma shortages. Issues related to PAHPA.
Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE JED FOUNDATION via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · 4T
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act.
General education about mental health and suicide prevention programs.
General education about mental health and suicide prevention programs. H.R.5740 - Enhancing Mental Health and Suicide Prevention Through Campus Planning Act. S.1409--Kids Online Safety Act.
ZOETIS via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158).
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Support for obesity drug coverage and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421). American Relief Act (P.L. 118-158).
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821). American Relief Act (P.L. 118-158).
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Outreach on renewable energy project in Taoyuan City, Taiwan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORD MOTOR COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Issues related to electric vehicles. H.R.7980 - End Chinese Dominance of Electric Vehicles in America Act of 2024.
Issues related to electric vehicles and charging infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLONIAL PIPELINE via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Pipeline Safety. Implementation of The Protecting Our Infrastructure of Pipelines and Enhancing Safety Act of 2020 (Division R of the Consolidated Appropriations Act, 2021 (PL 116-260)). Pipeline Safety Reauthorization legislation, including the "Pipeline Safety, Modernization, and Expansion Act of 2023"(H.R.7655), the Promoting Innovation in Pipeline Efficiency and Safety Act of 2023 (H.R. 6494), and proposals to address idled pipelines. Fueling Aviation's Sustainable Transition via Sustainable Aviation Fuels (FAST-SAF) grant. The "Next Generation Pipelines Research and Development Act" (HR 7073).
Provide information regarding Colonial Pipeline and its operations, its role in delivering refined products, and potential new projects. General issues affecting interstate refined product pipelines. Pipeline and energy infrastructure cybersecurity, including TSA security directives, and Enhancing Surface Cyber Risk Management Notice of Proposed Rulemaking (89 FR 88488-88592).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLVD HEALTH via WILLIAMS AND JENSEN, PLLC
2024 · fourth_quarter · Q4
Promote and educate Congress Administration and health orgnizations on the value of AvertD and other SOLVD products
Promote and educate Congress Administration and health orgnizations on the value of AvertD and other SOLVD products.
Promote and educate Congress Administration and health orgnizations on the value of AvertD and other SOLVD products
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ZOETIS via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
General agricultural issues important to livestock producers, animal health and related policy issues. Issues impacting medicines and vaccines for animals; Innovative FEED Act (S. 1842, H.R. 6687).
Animal health , issues impacting medicines and vaccines for animals. Innovative FEED Act (S.1842, H.R. 6687).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI, U.S. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Medicare coverage issue for non-opioid product.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PFIZER via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Issues related to pharmaceutical manufacturing and development. Legislative proposals related to WTO TRIPS Waiver.
OWENS & MINOR, INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Legislation to reauthorize the Pandemic & All-Hazards Preparedness Act ("PAHPA") to include the Preparing for All Hazards & Pathogens Reauthorization Act (H.R. 4421).
FY25 Appropriations
Issues related to durable medical equipment reimbursement including the DMEPOS Relief Act of 2023 (H.R. 5555), Competitive Bidding Relief Act of 2023 (S. 1294), Consolidated Appropriations Act, 2024 (P.L. 118-42), Further Consolidated Appropriations Act, 2024 (P.L. 118-47), and Supplemental Oxygen Access Reform (SOAR) Act of 2024 (S. 3821).
NOVO NORDISK INC. via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Support for obesity drug coverage and access.
Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I SQUARED CAPITAL ADVISORS (US) LLC via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Outreach on renewable energy project in Taoyuan City, Taiwan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORD MOTOR COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Issues related to electric vehicles. H.R.7980 - End Chinese Dominance of Electric Vehicles in America Act of 2024.
Issues related to electric vehicles and charging infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & COMPANY via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023, H.R. 4818, S. 2407. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARGENTUM MEDICAL via WILLIAMS AND JENSEN, PLLC
2024 · third_quarter · Q3
Educate and inform Members about a FDA proposed rule. Reclassification of wound care products and the potential consequences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, 340B reform, FDA drug approval.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical manufacturing and development, trade and tariffs. Legislative proposals related to WTO TRIPS Waiver.
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about mental health and suicide prevention programs. Increased funding for Garrett Lee Smith and Project AWARE mental health and suicide prevention programs
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FY25 Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; drug importation; and drug shortages. Drug pricing proposals. Medicare rebate reform, the 340B program, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). PASTEUR Act. Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Pharmacy benefit manager reform proposals. Public Law 118-47.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE